Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Increase in Short Interest

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 595,300 shares, a growth of 13.6% from the December 15th total of 523,900 shares. Based on an average trading volume of 260,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 7.5% of the company’s stock are short sold.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CTXR. Point72 DIFC Ltd acquired a new stake in shares of Citius Pharmaceuticals in the 2nd quarter worth $29,000. XTX Topco Ltd purchased a new position in Citius Pharmaceuticals in the 3rd quarter worth $47,000. Miller Investment Management LP raised its stake in Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after acquiring an additional 49,640 shares during the last quarter. Virtu Financial LLC purchased a new position in Citius Pharmaceuticals in the 3rd quarter worth $50,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Citius Pharmaceuticals in the 2nd quarter worth $69,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $3.30 on Friday. The stock has a market capitalization of $25.50 million, a price-to-earnings ratio of -0.55 and a beta of 1.30. Citius Pharmaceuticals has a 1-year low of $2.44 and a 1-year high of $26.75. The business has a fifty day moving average price of $4.09 and a 200-day moving average price of $10.94.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CTXR. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.